BRCA2
HGNC ↗12 article(s) in the watch · Cancer genetics
BRCA2 is a homologous-recombination tumour-suppressor gene. Pathogenic variants raise the risk of breast (female and male), ovarian, prostate and pancreatic cancer and enable access to PARP inhibitors.
Curated publications
Measuring disease likelihood in genomic ascertainment.
Secondary findings in genome sequencing — BRCA1/BRCA2: likelihood of genuine clinical diagnosis
Functional characterization of BRCA2 variants of uncertain significance identified in Korean breast cancer patients.
Hereditary breast cancer (BRCA2 variants of uncertain significance)
Comprehensive evidence for the pathogenicity of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in Japanese hereditary breast and ovarian cancer.
Hereditary breast and ovarian cancer (HBOC)
Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.
HR-positive/HER2-negative metastatic breast cancer in BRCA2 carriers
The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.
Hereditary prostate cancer predisposition
Comprehensive analysis of BRCA1/2 germline mutations in high-grade prostate cancer among Arab patients.
Hereditary prostate cancer / BRCA1/2
Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey.
Pancreatic adenocarcinoma with germline predisposition
Uptake of cascade tests in relatives of patients undergoing cancer precision medicine in Japan.
Germline variants identified through cancer precision medicine — cascade testing of relatives (BRCA1/2, ATM, MSH2, APC, BAP1, CDK4, CDKN2A, RAD51C)
Decoding the BRCA2 reversion principles underlying PARP inhibitor resistance.
Germline BRCA2 cancer — PARP inhibitor resistance mechanisms through reversion mutations
Surgical Outcomes After Risk-Reducing Mastectomy Among BRCA1 and BRCA2 Carriers
HBOC — surgical safety data for risk-reducing mastectomy
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
gBRCA1/2 breast cancer, early stage (triple negative or luminal)
Clinical impact of germline pathogenic variants in high-risk prostate cancer treated with radiotherapy.
High-risk prostate cancer and germline predisposition variants
Frequently asked questions
How is a BRCA2-related condition inherited?+
Autosomal dominant
What is the clinical spectrum associated with BRCA2?+
Breast (female/male), ovary, prostate, pancreas, melanoma
What is the management associated with BRCA2?+
Enhanced surveillance, risk-reducing surgery, PARP inhibitors.
How many Geno'X publications cover the BRCA2 gene?+
12 publication(s) on BRCA2 have been selected, summarised and scored by Geno'X on a public grading grid (domains: Cancer genetics).
